Carlyle Group (CG)
(Delayed Data from NSDQ)
$46.33 USD
+1.59 (3.55%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $46.35 +0.02 (0.04%) 4:24 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Price, Consensus and EPS Surprise
CG 46.33 +1.59(3.55%)
Will CG be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CG based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CG
Why Carlyle Group (CG) is a Top Dividend Stock for Your Portfolio
Discover (DFS) Q2 Earnings Beat on High Interest Income
CG: What are Zacks experts saying now?
Zacks Private Portfolio Services
Baxter (BAX) Shares Rise 2.4% in July: Will It Go Higher?
Carlyle Group (CG) Eyes Buyout of Baxter's Kidney Care Unit
Company News for July 8, 2024
Other News for CG
Carlyle Credit Income Fund Schedules Third Quarter 2024 Financial Results and Investor Conference Call
Carlyle's $4B Purchase Of Baxter's Kidney Division Backed By Ares And HPS Financing
Carlyle lines up $3B credit facility for Baxter unit, Bloomberg reports
Artisan Mid Cap Value Fund Q2 2024 Commentary
Moderna appoints David Rubenstein to board of directors